Here’s how top-performing cardiology programs set a tone that supports leadership and creates a culture aimed at success.

Despite a steady stream of hype and "pockets" of change, most cardiologists aren’t seeing the transformation that Silicon Valley promised. ACC CIO John Rumsfeld, MD, PhD, explains what's missing and why engaging clinical partners could help.

Drugmaker AstraZeneca announced Jan. 6 that its SGLT2 inhibitor dapagliflozin, sold commercially as Farxiga, had been granted Priority Review by the FDA for patients with heart failure with reduced ejection fraction.

The Heart Rhythm Society and Consumer Technology Association will debut new consumer guidelines this week focused on wearables that detect and monitor cardiovascular metrics.

Despite its diagnostic and prognostic value, speckle-tracking strain echocardiography is underused, some cardiac imagers say. What will it take for adoption to pick up?

Tread carefully, analysts warn. In the era of value-based healthcare, it may take more than shopworn business strategies to close the budget gap.

After a slow start, cardiac ERAS is gaining traction in some U.S. hospitals. Proponents explain how to overcome resistance. 

A New York cardiologist is suing tech giant Apple over its heartbeat-monitoring smartwatch capabilities, claiming the company lifted his patented HR intervention and has been using the technology without his permission.

Multidisciplinary teams are leveraging advanced technologies to explore the link between cardiovascular disease and dementia with an eye toward improving the diagnosis and treatment of both. 

In this first magazine of the 2020s, CVB invites the cardiology community to consider new mindsets for a number of areas, from treating dementias to tackling authorizations, documentation and collections.